Tempus AI (TEM) said Wednesday it has entered a multiyear collaboration with BioNTech (BNTX) to use its multimodal datasets to support the biotechnology company's oncology pipeline.
Under the collaboration, Tempus will provide analytical support and BioNTech will use its database to produce new insights into the biological mechanisms supporting the discovery of new therapies for cancer patients.
Tempus shares were up 1.1% in recent trading, while BioNTech was unchanged.
Price: 53.15, Change: +1.06, Percent Change: +2.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.